fxs_header_sponsor_anchor

News

Dr. Fauci: Rushing out a vaccine could jeopardize testing of others

Dr. Anthony Fauci, the head of the US National Institute of Allergy and Infectious Diseases, said in a Reuters interview late Monday, rushing out vaccines could undermine trials of other promising candidates.

Additional comments

“The one thing that you would not want to see with a vaccine is getting an EUA (emergency use authorization) before you have a signal of efficacy.”

“One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial.” 

“The FDA’s guidance on vaccines - both for full approval and for an EUA - explicitly requires a demonstration that it is both safe and effective.”

“To me, it’s absolutely paramount that you definitively show that a vaccine is safe and effective, both.”

“We would hope that nothing interferes with the full demonstration that a vaccine is safe and effective.”

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2026 FOREXSTREET S.L., All rights reserved.